Stuart L. Cramer
Expertise in
11
conditions

Dr. Stuart L. Cramer

Pediatric Hematology Oncology
7 Medical Park Rd Suite 7215, 
Columbia, SC 
Accepting New Patients
Referral may be required
Before you request
Expertise in
11
conditions
7 Medical Park Rd Suite 7215, 
Columbia, SC 

Overview

Stuart Cramer is a Pediatric Hematologist Oncology provider practicing medicine in Columbia, South Carolina.

Dr. Cramer is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Neuroblastoma, Histiocytosis, Reticulohistiocytoma, Hepatoblastoma, and Bone Marrow Aspiration.

Dr. Cramer is board certified in American Board Of Pediatrics. He is actively involved in clinical research, co-authoring 14 peer reviewed articles and participating in 48 clinical trials. Dr. Cramer is currently accepting new patients.

Specialties

Pediatric Hematology Oncology

Licenses

Pediatrics in AL

Board Certifications

American Board Of Pediatrics

Fellowships

University of Alabama Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Absolute Total Care South Carolina
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 7 Less Insurance Carriers -

Locations

Prisma Health Pediatric Hematology/Oncology
7 Medical Park Rd Suite 7215, Columbia, SC 29203

Additional Areas of Focus

Dr. Cramer has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)
Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

47 Clinical Trials

A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Radiation, Drug, Biological, Other
Study Drugs: Cyclophosphamide, Dactinomycin, Irinotecan hydrochloride, Temsirolimus, Vincristine sulfate, Vinorelbine
Study Phase: Phase 3
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Enrollment Status: Active_not_recruiting
Publish Date: August 25, 2026
Intervention Type: Drug, Other, Procedure
Study Drugs: Carboplatin, Cisplatin, Doxorubicin, Etoposide, Fluorouracil, Gemcitabine, Irinotecan, Oxaliplatin, Sorafenib, Vincristine Sulfate
Study Phase: Phase 3
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Enrollment Status: Active_not_recruiting
Publish Date: August 25, 2026
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide
Study Phase: Phase 3
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: August 24, 2026
Intervention Type: Biological, Drug, Procedure, Radiation
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide Phosphate, Filgrastim, Nivolumab, Pegfilgrastim, Prednisolone, Prednisone, Rituximab, Rituximab+Hyaluronidase Human, Vincristine Sulfate
Study Phase: Phase 3
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
Enrollment Status: Active_not_recruiting
Publish Date: August 19, 2026
Intervention Type: Drug, Procedure, Other, Biological
Study Drugs: Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Dexrazoxane Hydrochloride, Doxorubicin, Etoposide, Filgrastim, Ifosfamide, Imatinib Mesylate, Leucovorin Calcium, Mercaptopurine, Methotrexate, Methylprednisolone, Pegaspargase, Prednisolone, Hydrocortisone, Thioguanine, Vincristine Sulfate
Study Phase: Phase 3
A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
Enrollment Status: Active_not_recruiting
Publish Date: August 13, 2026
Intervention Type: Other, Procedure, Drug
Study Drugs: Carboplatin, Selumetinib Sulfate, Vincristine Sulfate
Study Phase: Phase 3
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Drug, Biological, Procedure, Other, Radiation
Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Filgrastim, Nivolumab, Pegfilgrastim, Vinblastine
Study Phase: Phase 3
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients With Tumors Harboring RET Gene Alterations
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients With Tumors Harboring RET Gene Alterations
Enrollment Status: Active_not_recruiting
Publish Date: August 03, 2026
Intervention Type: Procedure, Drug
Study Drug: Selpercatinib
Study Phase: Phase 2
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Enrollment Status: Completed
Publish Date: July 31, 2026
Intervention Type: Drug, Behavioral, Other, Procedure
Study Drug: 6-Mercaptopurine
Study Phase: Phase 3
A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy With Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) Plus VINO-CPO Maintenance in Patients With High Risk Rhabdomyosarcoma (HR-RMS)
A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy With Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) Plus VINO-CPO Maintenance in Patients With High Risk Rhabdomyosarcoma (HR-RMS)
Enrollment Status: Active_not_recruiting
Publish Date: July 30, 2026
Intervention Type: Procedure, Drug, Biological, Radiation
Study Drug: Cyclophosphamide
Study Phase: Phase 3
View 9 Less Clinical Trials

14 Total Publications

Neighborhood socioeconomic status and overall survival among children with acute lymphoblastic leukemia.
Neighborhood socioeconomic status and overall survival among children with acute lymphoblastic leukemia.
Journal: Blood advances
Published: May 02, 2025
Similar Doctors
Expertise in
8
conditions
Dr. Carla W. Roberts
Pediatric Hematology Oncology
Expertise in
8
conditions
Dr. Carla W. Roberts
Pediatric Hematology Oncology
Referral may be required
Before you request

Prisma Health Sickle Cell Clinic–Farrow Road

3010 Farrow Road, Suite 300, 
Columbia, SC 
 (5.2 miles away)
803-434-6100
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Carla Roberts is a Pediatric Hematologist Oncology provider practicing medicine in Columbia, South Carolina. Dr. Roberts is highly rated in 8 conditions, according to our data. Her clinical expertise encompasses Sickle Cell Disease, Hemoglobinopathy, Hemoglobin SC Disease, and Congenital Hemolytic Anemia. Dr. Roberts is board certified in American Board Of Pediatrics. Dr. Roberts is currently accepting new patients.

Expertise in
2
conditions
Dr. Evangeline J. Brown
Pediatric Hematology Oncology
Expertise in
2
conditions
Dr. Evangeline J. Brown
Pediatric Hematology Oncology
Referral may be required
Before you request

Prisma Health Pediatric Hematology–14 Medical Park

14 Medical Park Ste 410, 
Columbia, SC 
 (0.1 miles away)
803-434-3094
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Evangeline Brown is a Pediatric Hematologist Oncology provider practicing medicine in Columbia, South Carolina. Dr. Brown is highly rated in 2 conditions, according to our data. Her clinical expertise encompasses Sickle Cell Disease, Hemoglobin SC Disease, Thalassemia, and Alpha Thalassemia. Dr. Brown is board certified in American Board Of Pediatrics. Dr. Brown is currently accepting new patients.

Expertise in
3
conditions
Dr. Shilpa B. Shivakumar
Pediatric Hematology Oncology
Expertise in
3
conditions
Dr. Shilpa B. Shivakumar
Pediatric Hematology Oncology
Referral may be required
Before you request

Prisma Health Pediatric Hematology/Oncology

7 Medical Park Rd Suite 7215, 
Columbia, SC 
 (0.1 miles away)
803-434-3533
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Shilpa Shivakumar is a Pediatric Hematologist Oncology provider practicing medicine in Columbia, South Carolina. Dr. Shivakumar is highly rated in 3 conditions, according to our data. Her clinical expertise encompasses Fanconi Anemia, Shwachman-Diamond Syndrome, Ataxia-Pancytopenia Syndrome, and Pure Red Cell Aplasia. Dr. Shivakumar is board certified in American Board Of Pediatrics. Dr. Shivakumar is currently accepting new patients.

Frequently Asked Questions about Dr. Stuart L. Cramer

How do I make an appointment with Dr. Stuart L. Cramer?

You can book an appointment with Dr. Stuart L. Cramer by calling their office at 803-434-3533. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Stuart L. Cramer a top-rated expert for Neuroblastoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Stuart L. Cramer is classified as an Advanced expert for Neuroblastoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Stuart L. Cramer specialize in?

While Dr. Stuart L. Cramer is a Pediatric Hematology Oncology, they have specific expertise in Neuroblastoma, Histiocytosis, and Reticulohistiocytoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Pediatric Hematology Oncology.

Does Dr. Stuart L. Cramer participate in research or clinical trials?

Yes. Dr. Stuart L. Cramer has published 14 articles and abstracts on conditions like Neuroblastoma. You can view a list of Dr. Stuart L. Cramer's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Stuart L. Cramer accept my insurance?

Dr. Stuart L. Cramer accepts most major insurance plans, including Absolute Total Care South Carolina and Aetna. We recommend calling the office directly at 803-434-3533 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Cramer's expertise for a condition
ConditionClose
      View All 11 Advanced Conditions
      View All 18 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile